oramed_ml

Jan 30 (Reuters) – Oramed, an Israeli developer of oral drug delivery systems, said on Thursday a mid-stage trial for its oral insulin capsule for the treatment of type 2 diabetes met all primary and secondary endpoints.

During the Phase 2a trial, conducted under a U.S. Food and Drug Administration new drug protocol, 30 patients with type 2 diabetes took part in an in-patient setting for one week.

Endpoints of safety as well as pharmacodynamic and pharmacokinetic effects were evaluated.

READ MORE

Leave a comment

Your email address will not be published.